Autism biomarkers LinusBio is actively expanding into autism biomarker discovery and diagnostics with ClearStrand-ASD and partnerships with autism-focused organizations, presenting a clear sales opportunity for neurodevelopmental diagnostic tools, payer discussions, and clinical adoption support.

Exposome testing The launch of traced, the first consumer exposome test, signals demand for actionable exposome data in consumer health screening and potential clinician integrations, offering partnerships with wearables, labs, and healthcare providers for data translation and analytics services.

Strategic partnerships Recent collaborations with Coralis Health and the BRAIN Foundation indicate a channel strategy targeting neurodiversity care ecosystems, suggesting opportunities to co-develop educational programs, payer-ready endpoints, and early intervention workflows.

Funding momentum With multi-million VC funding and a growing pipeline in precision exposome medicine, there is a window to propose pilot programs, contract R&D, and early-access trials for pharma, biotech, and contract research organizations seeking novel molecular endpoints.

Clinical endpoints LinusBio focuses on disease domains lacking molecular endpoints, including CNS and oncology; this positions the company to engage pharma and clinical trial sponsors in need of innovative biomarkers and endpoints to enable new trial designs and regulatory submissions.